Everolimus Tablet
Product Images NDC 72603-256

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 72603-256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel Package Label 10 mg (10 mg Bottle Label)

Everolimus Tablets 10 mg oral tablets packaging label. The label shows a 30-tablet count, with storage instructions to keep at 20° to 25°C and protect from light and moisture. Manufactured by Biocon Pharma Limited in India and labeled for NorthStar Rx LLC, Memphis, TN. The label indicates the package is child-resistant and includes dispensing cautions.*

FDA Label Image

Principal Display Panel Package Label 2.5 mg (2.5 mg Bottle Label)

Packaging label for Everolimus Tablets 2.5 mg oral tablets, containing 30 tablets per container. The label includes storage instructions, child-resistant packaging notice, and manufacturing details by Biocon Pharma Limited for NorthStar Rx LLC. The NDC is 72603-254-01.*

FDA Label Image

Principal Display Panel Package Label 5 mg (5 mg Bottle Label)

Everolimus Tablets 5 mg oral tablets packaging label by NorthStar Rx LLC. The label indicates 30 tablets per package, with storage instructions and manufacturer details for Biocon Pharma Limited, Bengaluru, India. The NDC number visible is 72603-255-01.*

FDA Label Image

Principal Display Panel Package Label 7.5 mg (7.5 mg Bottle Label)

Everolimus Tablets 7.5 mg oral tablets packaging label. The label shows a 30-tablet bottle by NorthStar Rx LLC, manufactured by Biocon Pharma Limited in India. The label includes dosage and storage instructions and a barcode on the right side.*

FDA Label Image

Everolimus Structural Formula (Everolimus Structure)

Chemical structure diagram of everolimus, the active ingredient in EVEROLIMUS tablets. The image depicts the molecular arrangement of everolimus, showing its atoms and bonds in a skeletal formula format.*

FDA Label Image

Figure 1: Kaplan-meier Progression-free Survival Curves (investigator Radiological Review) (Fig 1)

Kaplan-Meier survival curve showing progression-free survival probability (%) over time in months for two groups: one treated with Everolimus 10 mg plus exemestane, and a placebo plus exemestane group. The graph includes censoring times and shows a hazard ratio of 0.45 with a 95% confidence interval, indicating a statistically significant difference with a logrank p value of less than 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.